Epalex
EpaleX, based in San Francisco, develops innovative inhaled treatments for epilepsy and migraines, enabling rapid seizure and attack control.
Founded
2009EpaleX, based in San Francisco, develops innovative inhaled treatments for epilepsy and migraines, enabling rapid seizure and attack control.
EpaleX, founded in San Francisco, is a clinical-stage pharmaceutical company dedicated to developing innovative inhaled treatments for epilepsy and migraines. The company's core mission is to provide rapid and effective seizure and migraine control through novel therapeutic approaches. EpaleX's flagship product is a pocket nebulizer that delivers a powerful antiseizure medication directly to the brain, enabling patients to prevent full-blown seizures upon detecting early warning signs. The company focuses on addressing the unmet needs of patients who are inadequately treated by existing therapies.
Notable figures associated with EpaleX include leading neurologists and pharmaceutical experts who contribute to its groundbreaking research. The company has attracted significant investment from venture capital firms specializing in healthcare innovations. Key achievements include successful preclinical trials demonstrating the efficacy and safety of their inhaled treatments. EpaleX's impact is profound, offering hope to millions of epilepsy and migraine sufferers worldwide by providing a new mechanism of action that overcomes drug resistance and improves quality of life.
Companies similar to Epalex include Epitel, NeuroPace, Cerebral Therapeutics and Bryn Pharma.
Epalex was founded in 2009.
Epalex's headquarters is located in Palo Alto, CA, US.
Epalex's most recent funding round was for $500k (USD) in January 2024.
As of Jan 1, 2024, Epalex has disclosed funding of $26.1M (USD). Undisclosed round amounts are excluded.
Epalex has 5 employees as of Feb 5, 2024.
Bryn Pharma
brynpharma.com
